What we do

For more than 45 years we’ve been creating high-quality medicines and making them accessible to the people who need them.

Learn more about how we do this across North America, MENA and Europe.

Investors

Together we are building a leading generics and specialty pharmaceutical company where everyone can thrive.

Learn more about our strategy, investment case and track record of success.

Responsibility

Learn more about how we put better health within reach, every day and make a difference to people’s lives.

Careers

We're looking for people who share our passion and want to help us make a real difference in the world.

Newsroom

Featured

Press Release, Corporate 28 June 2025

Hikma receives FDA approval for TYZAVANTM (Vancomycin Injection, USP) in the US Press Release, Product 02 July 2025 Hikma receives FDA approval for TYZAVANTM (Vancomycin Injection, USP) in the US
Hikma publishes its 2024 Sustainability Report reinforcing commitment to global access to medicines Press Release, Corporate 30 June 2025 Hikma publishes its 2024 Sustainability Report reinforcing commitment to global access to medicines
Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines Press Release, Corporate 28 June 2025 Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines
Hikma launches Methylene Blue Injection, USP in the US Press Release, Product 25 June 2025 Hikma launches Methylene Blue Injection, USP in the US